Quantum BioPharma
- Country
- Ownership
- -
- Employees
- 8
- Market Cap
- -
- Introduction
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Huge Biopharma Australia Pty Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06595706
- Locations
- 🇦🇺
Cmax Clinical Research, Adelaide, Maryland, Australia
Assessing the Safety and Efficacy of FSD-F2R6-A-CP in Volunteers in an Induced State of Alcohol Intoxication
- Conditions
- Acute Alcohol Intoxication
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Quantum Biopharma
- Target Recruit Count
- 26
- Registration Number
- NCT06505239
- Locations
- 🇺🇸
Applied Science and Performance Institute, Tampa, Florida, United States
News
Quantum BioPharma Secures $600 Private Placement to Advance Multiple Sclerosis Drug Development
Quantum BioPharma announced a $600 private placement of class A multiple voting shares at $50 per share to fund general working capital purposes.
Quantum BioPharma Advances Novel PET Imaging Biomarker for Multiple Sclerosis with First Patient Scan
Quantum BioPharma and Massachusetts General Hospital have successfully scanned the first multiple sclerosis patient using a novel [18F]3F4AP PET imaging technique designed to monitor demyelination.
Quantum BioPharma's UnbuzzdTM Shows 40% Faster Alcohol Metabolism in Clinical Trial
Clinical trial demonstrates UnbuzzdTM dietary supplement accelerates alcohol metabolism by 40% within 30 minutes compared to placebo, while improving alertness and stabilizing vital signs.
Quantum BioPharma Advances Lucid-21-302 Clinical Trial for Multiple Sclerosis
Quantum BioPharma's Lucid-21-302, a potential treatment for multiple sclerosis, has progressed to the second cohort dosing phase after positive safety review.
Phase 1 Trial of Lucid-MS Initiated to Protect Myelin Sheath in Multiple Sclerosis
Quantum Biopharma's Lucid-21-302, a potential oral treatment for multiple sclerosis (MS), has entered a Phase 1 safety and tolerability trial in healthy adults.